Gain Therapeutics, Inc. (GANX): Total Liabilities
$4.25M
As of 2025-12-31
$4.13M
As of 2026-06-30
-6.6%
3-year compound annual growth
+4.6%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.25M | -11.1% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $4.78M | -20.7% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $6.03M | +15.5% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $5.22M | +25.3% | 2024-03-26, Balance as of period end |
| 2021-12-31 | $4.17M | +22.5% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $3.40M | n/a | 2022-03-25, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Gain Therapeutics, Inc. (GANX) | 2025-12-31 | $4.25M | -11.1% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $4.66M | +20.0% |
| Faeth Therapeutics, Inc. (FTH) | 2025-12-31 | $4.31M | -38.2% |
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | $7.12M | +24.5% |
| Immunic, Inc. (IMUX) | 2025-12-31 | $30.73M | +36.9% |
| Rein Therapeutics, Inc. (RNTX) | 2025-12-31 | $7.24M | -7.2% |
| Phio Pharmaceuticals Corp. (PHIO) | 2025-12-31 | $1.34M | +32.0% |
| Kiora Pharmaceuticals Inc (KPRX) | 2025-12-31 | $8.13M | -24.2% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $85.04M | +6.2% |
Compare GANX, CRVO, FTH, MBRX side by side · Screen every company in Pharmaceutical Preparations ↗